Diabetes After Transplant Carries Different Risks by Organ
Diabetes complicates solid organ transplantation in ways that are easy to miss if clinicians focus only on graft survival. A large multi-organ analysis presented at ENDO 2026 found that diabetes is linked to higher long-term mortality after kidney, liver, heart, and lung transplantation, but the risk pattern changes depending on the organ and on whether diabetes was present before transplant or developed afterward.
The most clinically striking result was not simply that diabetes mattered. It was that the direction and strength of risk shifted across organ systems, with a 6.8-fold variation in diabetes burden between groups. In kidney and liver recipients, preexisting diabetes generally carried the heavier mortality penalty. In heart and lung recipients, new-onset diabetes after transplant showed the stronger association with death.
One sentence captures the bedside implication: transplant medicine does not have a single diabetes problem; it has several.
Why Immunosuppression Creates a Metabolic Trap
The biology behind post-transplant diabetes has long been known, but the practical consequences remain difficult to manage. Immunosuppression preserves the graft, yet the same drugs that prevent rejection can worsen glucose homeostasis. Glucocorticoids increase insulin resistance, making peripheral tissues less responsive to circulating insulin. Calcineurin inhibitors such as tacrolimus and cyclosporine protect transplanted organs by suppressing T-cell activity, but they also interfere with pancreatic beta-cell function and insulin release.
That creates a familiar transplant dilemma. Lowering immunosuppression to protect metabolism can increase rejection and mortality, leaving clinicians with limited room to maneuver. The analysis did not solve that tradeoff, but it sharpened where the danger seems greatest and when monitoring should intensify.
Kidney and Liver Recipients Enter Transplant With More Diabetes
Using registry data from the federal Organ Procurement and Transplantation Network, Mishal Ali and Alan L. Hutchison analyzed 803,762 transplant recipients from 1987 through 2021. Their first pass through the data showed that baseline diabetes was especially common in kidney recipients, where about one in three patients already had diabetes at the time of transplant.
That matters because preexisting diabetes brings a heavier burden into surgery from the start. Patients arrive with more advanced metabolic disease, a greater likelihood of vascular injury, and a longer path to postoperative recovery. After transplant, the need for immunosuppression can magnify those vulnerabilities rather than erase them. In kidney and liver recipients, the survival curves reflected exactly that pattern: diabetes present before transplant generally predicted worse mortality than diabetes diagnosed later.
A separate clinical point follows from those numbers. Recipients with known diabetes before transplant are not simply diabetic patients who happen to receive a new organ. They are a high-risk population whose cardiovascular and metabolic reserve is already constrained before the first postoperative dose of immunosuppression.
Heart and Lung Recipients Show a Different Postoperative Pattern
Thoracic transplant recipients stood apart. Around one year after transplant, heart and lung recipients showed a sharp rise in new-onset diabetes after transplant, and roughly one in four developed diabetes over 15 years. The analysis split follow-up into non-cumulative windows, which makes the first-year comparison with later years imperfect, but the pattern still deserves attention because the early post-transplant period is when immunosuppression is often most intense.
For heart and lung transplantation, several biologic explanations likely overlap. Underlying diseases may already distort glucose metabolism before surgery. Cystic fibrosis, a major indication for lung transplantation, affects the pancreas as well as the lungs, so diabetes may be present but unrecognized before transplant or may continue to evolve afterward despite a successful graft. Thoracic recipients may also require more aggressive immunosuppression than liver recipients, increasing the metabolic cost of preserving graft function.
In these groups, diabetes may arrive as a delayed complication of lifesaving therapy rather than as a baseline diagnosis. The survival impact of that shift was more pronounced than expected, especially in heart recipients, where new-onset diabetes carried higher mortality risk than preexisting diabetes.
Mortality Signals Persist Beyond the First Year
The analysis reinforced a point transplant teams may not communicate consistently once the surgical phase is over: the one-year milestone is not the end of the metabolic story. Mortality after the first year is driven largely by cardiovascular disease, and diabetes plus metabolic syndrome account for a substantial share of that burden. A new diagnosis of diabetes after transplant can therefore become more than a laboratory abnormality; it can mark a transition into a higher-risk cardiovascular trajectory.
That is why post-transplant follow-up cannot stop at graft function, tacrolimus levels, and rejection surveillance. Primary care clinicians eventually inherit these patients, and they need to know that a transplant recipient with new hyperglycemia is not a routine diabetes case. The interaction between immunosuppression, organ-specific physiology, and cardiovascular risk makes the treatment pathway more fragile than it appears from the outside.
Organ-Specific Prevention Still Looks Hard, but Surveillance Is Immediate
The study does not suggest a simple universal intervention. Earlier attempts to reduce diabetes by adjusting immunosuppression increased rejection and mortality, which is why the field has remained stuck in place for years. What this analysis adds is a more refined map of where prevention and surveillance may matter most.
Heart and lung recipients may need particularly close glucose monitoring during the first year, when diabetes incidence rises sharply. Kidney and liver recipients may need more aggressive attention to preexisting metabolic disease before transplant, because baseline diabetes already places them at a survival disadvantage. Across all four organs, the data argue for continuity between transplant centers and community clinicians, since the risk persists well after discharge.
A personalized plan before transplant may be the most plausible path forward. Physiologic signals, underlying disease, and expected immunosuppressive burden may help identify which patients are likely to develop diabetes and which are most likely to suffer the worst downstream consequences. For now, the clearest message is narrower: transplant teams should expect diabetes to behave differently in kidney, liver, heart, and lung recipients, and follow-up should be organized accordingly rather than by habit.